Your browser doesn't support javascript.
loading
Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial.
Newby, L Kristin; Marber, Michael S; Melloni, Chiara; Sarov-Blat, Lea; Aberle, Laura H; Aylward, Philip E; Cai, Gengqian; de Winter, Robbert J; Hamm, Christian W; Heitner, John F; Kim, Raymond; Lerman, Amir; Patel, Manesh R; Tanguay, Jean-Francois; Lepore, John J; Al-Khalidi, Hussein R; Sprecher, Dennis L; Granger, Christopher B.
Afiliación
  • Newby LK; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA. Electronic address: kristin.newby@duke.edu.
  • Marber MS; King's College London BHF Centre, Cardiovascular Division, Rayne Institute, St Thomas' Hospital, London, UK.
  • Melloni C; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
  • Sarov-Blat L; Heart Failure Discovery Performance Unit, GlaxoSmithKline, Philadelphia, PA, USA.
  • Aberle LH; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
  • Aylward PE; South Australian Health and Medical Research Institute, Flinders University and Medical Centre, Adelaide, SA, Australia.
  • Cai G; Heart Failure Discovery Performance Unit, GlaxoSmithKline, Philadelphia, PA, USA.
  • de Winter RJ; Department of Cardiology, Academic Medical Center-University of Amsterdam, Amsterdam, Netherlands.
  • Hamm CW; Kerckhoff Heart and Thoraxcenter, Bad Nauheim, Germany.
  • Heitner JF; Division of Cardiology, New York Methodist Hospital, Brooklyn, NY, USA.
  • Kim R; Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
  • Lerman A; Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.
  • Patel MR; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
  • Tanguay JF; Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada.
  • Lepore JJ; Heart Failure Discovery Performance Unit, GlaxoSmithKline, Philadelphia, PA, USA.
  • Al-Khalidi HR; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
  • Sprecher DL; Heart Failure Discovery Performance Unit, GlaxoSmithKline, Philadelphia, PA, USA.
  • Granger CB; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
Lancet ; 384(9949): 1187-95, 2014 Sep 27.
Article en En | MEDLINE | ID: mdl-24930728
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Piridinas / Ciclopropanos / Proteínas Quinasas p38 Activadas por Mitógenos / Inhibidores de Proteínas Quinasas / Infarto del Miocardio Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Año: 2014 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Piridinas / Ciclopropanos / Proteínas Quinasas p38 Activadas por Mitógenos / Inhibidores de Proteínas Quinasas / Infarto del Miocardio Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Año: 2014 Tipo del documento: Article